Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: BRILINTA

« Back to Dashboard
Brilinta is a drug marketed by Astrazeneca Lp and is included in one NDA. It is available from three suppliers. There are five patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and thirteen patent family members in forty-four countries.

The generic ingredient in BRILINTA is ticagrelor. There are eighteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ticagrelor profile page.

Summary for Tradename: BRILINTA

Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: see list7

Clinical Trials for: BRILINTA

High Ticagrelor Loading Dose in STEMI
Status: Completed Condition: Coronary Artery Disease

Comparison of Administration Strategies of Ticagrelor in Patients With Unstable Angina Pectoris, a Pharmacokinetic / Pharmacodynamic Study
Status: Recruiting Condition: Unstable Angina Pectoris

Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor
Status: Completed Condition: Coronary Artery Disease; Acute Coronary Syndrome

Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis
Status: Recruiting Condition: End Stage Renal Disease; Vascular Access Patency

Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients
Status: Completed Condition: Coronary Artery Disease

In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients
Status: Completed Condition: Coronary Artery Disease

Cangrelor Ticagrelor Transition Study
Status: Completed Condition: Coronary Artery Disease

Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis
Status: Not yet recruiting Condition: Acute ST Segment Elevation Myocardial Infarction; Acute Coronary Syndrome

Reversal of the Anti-platelet Effects of Ticagrelor
Status: Recruiting Condition: Coronary Artery Disease

Impact of Ticagrelor Re-load on Pharmacodynamic Profiles
Status: Completed Condition: Coronary Artery Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Lp
BRILINTA
ticagrelor
TABLET;ORAL022433-002Sep 3, 2015RXNo7,265,124<disabled>YY <disabled>
Astrazeneca Lp
BRILINTA
ticagrelor
TABLET;ORAL022433-002Sep 3, 2015RXNo<disabled><disabled>
Astrazeneca Lp
BRILINTA
ticagrelor
TABLET;ORAL022433-002Sep 3, 2015RXNo6,251,910<disabled>Y <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: BRILINTA

Drugname Dosage Strength RLD Submissiondate
ticagrelorTablets60 mgBrilinta9/30/2015
ticagrelorTablets90 mgBrilinta7/20/2015

International Patent Family for Tradename: BRILINTA

Country Document Number Publication Date
Poland201283Mar 31, 2009
Russian Federation2012121883Nov 27, 2013
Taiwan530058May 01, 2003
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc